Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Sponsor: Shanghai Refreshgene Technology Co., Ltd.
Summary
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Official title: A Phase I/IIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2023-12-12
Completion Date
2030-12-31
Last Updated
2024-11-14
Healthy Volunteers
No
Interventions
RRG001
Administered via Subretinal injection. Dosage form: injection solution.
Locations (1)
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, China